Immunologic Products asdhealthcare.com
|
|
- Felicity McDaniel
- 5 years ago
- Views:
Transcription
1 Immunologic Products Bivigam Carimune NF Flebogamma DIF Gammagard S/D Low IGA Gammagard Liquid Gammaked Gammaplex Gamunex -C Hizentra HyQvia Octagam Privigen
2 Immunologic Products asdhealthcare.com Product Bivigam Carimune NF Flebogamma DIF Manufacturer Biotest Pharmaceuticals (800) biotestpharma.com bivigam.com CSL Behring (877) 355-IGIQ cslbehring.com Grifols (800) grifols.com Indications PI PID, ITP PIDD Contraindications IgA deficiency with antibodies against IgA and a history of hypersensitivity; anaphylaxis to IG IgA deficiency; IgA antibodies; anaphylaxis to IG Form Liquid Lyophilized Liquid Concentration 10% 3 / 6 / 9 / 12% 5% Sizes 5 / 10 gm 6 / 12 gm 2.5 / 5 / 10 / 20 gm Labelling for Removal of Pathogenic Prions Viral Removal Method Individuals who have had a history of anaphylactic or severe systemic reactions to the administration of human immune globulin and IgA deficient patients with antibodies to IgA and a history of hypersensitivity. N / A N / A Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Precipitation and removal of fraction III; solvent/ detergent treatment; 35 nm virus filtration; low ph ph 4 / Pepsin; fractionation nanofiltration; TSE removal IgA Content 200 µg / ml Trace <2400 µg / ml ( µg / ml) Average: < 3.2 mcg / ml Stabilizer Glycine; polysorbate Sucrose D-sorbitol (polyol) Sugar Content No sugar 1.67 g Sucrose 5% D-sorbitol (polyol) Sodium Content mmol / L Less than 20 mg NaCL / g protein Trace (< 3.2 mmol / L) ph ± 0.2 Average: 5.6 ± 0.1 Osmolality (mosm/kg) Pasteurization (60 C, 10 h), solvent detergent, dual sequential nanofiltration (35 nm and 20 nm), Fraction I precipitation, Fraction II + III incubation, 4% PEG precipitation and acid ph 4 treatment Half-Life 30 days 23 days 3-week dosing interval: 30 ± 9 days; 4-week dosing interval: 32 ± 5 days Storage 2 8 C; do not freeze 30 C; do not freeze 2 25 C; do not freeze Shelf-Life Can be stored until expiration date at 2 8 C 36 months 24 months RT Reconstitution Fluid/Diluent Administration N / A NaCI, D5W or SW; do not shake N/A Initial infusion rate: ml / kg / min; maintenance infusion rate: 0.06 ml / kg / min (if tolerated) 3 mg / kg / min ml / kg / min Some products may be stored ambient. To help maintain product integrity, products will only be accepted for return when they are shipped according to the return guidelines of ASD Healthcare and the product s manufacturer.
3 Flebogamma DIF Grifols (800) grifols.com Gammagard Liquid gammagardliquid.com Gammagard Liquid gammagardliquid.com PIDD Replacement therapy for PI in adults and children two years of age or older; maintenance therapy to improve muscle strength and disability in adult patients with MMN Replacement therapy for PI in adults and children two years of age or older; maintenance therapy to improve muscle strength and disability in adult patients with MMN Individuals who have had a history of anaphylactic or severe systemic reactions to the administration of human immune globulin and IgA deficient patients with antibodies to IgA and a history of hypersensitivity. IgA deficiency with antibodies against IgA and a history of hypersensitivity; anaphylactic or severe hypersensitivity to IG (Human) IgA deficiency with antibodies against IgA and a history of hypersensitivity; anaphylactic or severe hypersensitivity to IG (Human) Liquid Liquid Liquid 10% 10% 10% 5 / 10 / 20 gm 1 / 2.5 / 5 / 10 / 20 / 30 gm 1 / 2.5 / 5 / 10 / 20 / 30 gm Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Pasteurization (60 C, 10 h), solvent detergent, dual sequential nanofiltration (35 nm and 20 nm), Fraction I precipitation, Fraction II + III incubation, 4% PEG precipitation and acid ph 4 treatment N / A Solvent/detergent viral inactivation step; low ph viral inactivation step; nanofiltration Average: < 3.2 mcg / ml Average: 37 µg / ml Average: 37 µg / ml D-sorbitol (polyol) Glycine Glycine 5% D-sorbitol (polyol) No added sugars No added sugars Trace (< 3.2 mmol / L) No added sodium No added sodium Average: 5.5 ± week dosing interval: 34 ± 10 days; 4-week dosing interval: 37 ± 13 days 2 25 C; do not freeze N / A days days 2 8 C (36 46 F) refrigerate for 36 months; RT 25 C (77 F) for 12 months within first 24 months of date of manufacture; do not freeze Solvent / detergent viral inactivation step; low ph viral inactivation step; nanofiltration 2 8 C (36 46 F) refrigerate for 36 months; RT 25 C (77 F) for 12 months within first 24 months of date of manufacture; do not freeze 24 months RT 24 months RT; 36 months refrigerate 24 months RT; 36 months refrigerate N / A D5W only D5W only ml / kg / min 0.5 ml / kg / hr (0.8 mg / kg / min) for 30 mins initial, increase every 30 mins up to 5 ml / kg / hr maintenance For 40 kg BW: 30 ml / site at a rate of 20 ml / hr / site initial; 30 ml / site at a rate of 20 to 30 ml / hr / site maintenance; For <40kg BW: 20 ml / site at a rate of 15 ml / hr / site initial; 20 ml / site at a rate of 15 to 20 ml / hr / site maintenance While every effort has been made to ensure the accuracy and completeness of the information presented, the author, editor, or publisher cannot be responsible for any errors or omissions. All provided information is obtained from FDA approved product information ASD Healthcare. Chart updated November 2015.
4 Immunologic Products asdhealthcare.com Product Gammagard S/D Low IGA Gammaked Gammaked Manufacturer gammagard.com Kedrion BioPharma, Inc. (855) kedrion.com gammaked.com Kedrion BioPharma, Inc. (855) kedrion.com gammaked.com Indications PI in adults and children two years of age or older; prevention of bacterial infections in hypogammaglobulinemia and / or recurrent bacterial infections associated with B-cell CLL; prevention / control of bleeding in adult ITP; prevention of coronary artery aneurysms associated with Kawasaki syndrome in pediatrics ITP; PIDD; CIDP PI Contraindications IgA deficiency with antibodies against IgA and a history of hypersensitivity; anaphylactic or severe hypersensitivity to IG (Human) IgA deficiency with antibodies against IgA; anaphylaxis to IG IgA deficiency with antibodies against IgA; anaphylaxis to IG Form Lyophilized Liquid Liquid Concentration 5% 10% 10% Sizes 5 / 10 gm 1 / 2.5 / 5 / 10 / 20 gm 1 / 2.5 / 5 / 10 / 20 gm Labelling for Removal of Pathogenic Prions Viral Removal Method N / A N / A N / A Solvent / detergent Caprylate precipitation; filtration chromatography; low ph IgA Content <1 µg / ml in a 5% solution 46 µg / ml 46 µg / ml Stabilizer Glycine Glycine Glycine Sugar Content 20 mg / ml Glucose in a 5% solution No sugar No sugar Sodium Content Sodium chloride approximately 8.5 mg / ml in a 5% solution Trace Trace ph 6.8 ± Osmolality (mosm/kg) Half-Life 37.7 ± 15 days 35 days 35 days Caprylate precipitation; filtration chromatography; low ph Storage 25 C; do not freeze 2 8 C; do not freeze 2 8 C; do not freeze Shelf-Life 24 months RT 6 months RT; 36 months refrigerate 6 months RT; 36 months refrigerate Reconstitution Fluid/Diluent Administration SW; do not shake D5W only D5W only 5% infusion rate is 0.5 ml / kg / hr, initial; maximum rate is 4 ml / kg / hr as tolerated; 10% infusion rate is 0.5 ml / kg / hr, initial, maximum rate is 8 ml / kg / hr if no adverse effects occur; recommended maximum rates in patients at risk for renal dysfunction or thrombotic complications should be: <4 ml / kg / hr in a 5% solution; <2 ml / kg / hr in a 10% solution ml / kg / min ml / kg / min Some products may be stored ambient. To help maintain product integrity, products will only be accepted for return when they are shipped according to the return guidelines of ASD Healthcare and the product s manufacturer.
5 Gammaplex Bio Products Laboratory (866) bpl.co.uk gammaplex.com Gamunex -C Grifols (800) grifols.com Gamunex -C Grifols (800) grifols.com PI, ITP ITP; PIDD; CIDP PIDD IgA deficiency with antibodies against IgA; hereditary intolerance to fructose Individuals with known anaphylactic or severe systemic response to IG. Individuals with known antibodies against IgA should receive Gamunex-C with utmost cautionary measures due to risk of severe immediate hypersensitivity reactions including anaphylaxis. Liquid Liquid Liquid Individuals with known anaphylactic or severe systemic response to IG. Individuals with known antibodies against IgA should receive Gamunex-C with utmost cautionary measures due to risk of severe immediate hypersensitivity reactions including anaphylaxis. 5% 10% Immune Globulin Injection 10% Immune Globulin Injection 5 / 10 / 20 gm 1 / 2.5 / 5 / 10 / 20 / 40 gm 1 / 2.5 / 5 / 10 / 20 / 40 gm N / A Cold ethanol fractionation; ion exchange chromotography; solvent / detergent, nanofilitration (20 nm); ultrafiltration; terminal low ph Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Caprylate precipitation/depth filtration; caprylate incubation; depth filtration; column chromatography; low ph incubation <10 µg / ml Average: 46 mcg / ml Average: 46 mcg / ml Sorbitol; glycine; polysorbate-80 Glycine Glycine No sugar No sugar No sugar mmol / L Trace Trace mosm / kg; not less than 240 mosm / kg ± 26 days Approximately 35 days Approximately 35 days 2 25 C; do not freeze 2 8 C; do not freeze 2 8 C; do not freeze Yes; manufacturing process includes steps that provide a reasonable assurance that low levels of a vcjd model agent, if present in the starting material, would be removed Caprylate precipitation/depth filtration; caprylate incubation; depth filtration; column chromatography; low ph incubation 24 months 6 months RT; 36 months refrigerate 6 months RT; 36 months refrigerate N/A D5W only D5W only 0.6 ml / kg / hr for min; increase gradually as tolerated every 15 min to 4.8 ml / kg / hr ml / kg / min ml / kg / min While every effort has been made to ensure the accuracy and completeness of the information presented, the author, editor, or publisher cannot be responsible for any errors or omissions. All provided information is obtained from FDA approved product information ASD Healthcare. Chart updated November 2015.
6 Immunologic Products asdhealthcare.com Product Manufacturer Hizentra CSL Behring (877) 355-IGIQ cslbehring.com hizentra.com HyQvia hyqvia.com HyQvia Recombinant Human Hyaluronidase hyqvia.com Indications PI PI in adults PI in adults Contraindications IgA deficiency; anaphylaxis to polysorbate and IG; hyperprolinemia IgA deficiency with antibodies against IgA; anaphylaxis to IG; hypersensitivity to hyaluronidase or Recombinant Human Hyaluronidase of HyQvia Form Liquid Liquid Liquid Concentration 20% 10% 10% Sizes 1 / 2 / 4 / 10 gm 2.5 / 5 / 10 / 20 / 30 gm 1.25 / 2.5 / 5 / 10 / 15 gm Labelling for Removal of Pathogenic Prions Viral Removal Method N / A N / A N / A ph 4; virus and depth filtration; TSE removal Solvent/detergent viral inactivation step; low ph viral inactivation step; nanofiltration IgA Content 50 mcg / ml Average: 37 μg / ml 0 μg / ml IgA deficiency with antibodies against IgA; anaphylaxis to IG; hypersensitivity to Hyaluronidase or Recombinant Human Hyaluronidase of HyQvia Comprehensive virus testing at the Master Cell Bank, Working Cell Bank, and bulk harvest stage; effective virus reduction during the purification process; use of pharmaceutical grade human albumin Stabilizer L-proline Glycine Human albumin (1.0 mg / ml) Sugar Content No sugar No added sugar No added sugar Sodium Content Trace amounts <10 mmol / L No added sodium 8.5 mg / ml ph Osmolality (mosm/kg) Half-Life N / A N / A N / A Storage 2 25 C; do not freeze; do not shake 2 8 C for up to 36 months 2 8 C for up to 36 months Shelf-Life 30 months 3 months RT; 36 months refrigerated at 2 8 C; do not freeze Reconstitution Fluid/Diluent Administration N / A N / A N / A using infusion pump; 15 ml / hour for first infusion up to 25 ml / hour on subsequent infusions as tolerated Infusion requires an infusion pump capable of infusing a patient s therapeutic dose at infusion rates up to 300 ml / hr / site; the pump must have the ability to titrate the flow rate up or down if required to improve tolerability; to ensure maximum flow rates, use a subcutaneous needle set that is 24 gauge and labeled for high flow rates 3 months RT; 36 months refrigerated at 2 8 C; do not freeze Infusion requires an infusion pump capable of infusing a patient s therapeutic dose at infusion rates up to 300 ml / hr / site; the pump must have the ability to titrate the flow rate up or down if required to improve tolerability; to ensure maximum flow rates, use a subcutaneous needle set that is 24 gauge and labeled for high flow rates Some products may be stored ambient. To help maintain product integrity, products will only be accepted for return when they are shipped according to the return guidelines of ASD Healthcare and the product s manufacturer.
7 Octagam Octapharma (866) octapharma.com octagamus.net Octagam Octapharma (866) octapharma.com octagamus.net Privigen CSL Behring (877) 355-IGIQ cslbehring.com privigen.com PI ITP PI; ITP Anaphylactic or severe systemic reactions to human immunoglobulin; IgA deficient patients with antibodies against IgA and a history of hypersensitivity; patients with acute hypersensitivity reaction to corn History of anaphylactic or severe systemic reactions to human immunoglobulin; IgA deficient patients with antibodies against IgA and a history of hypersensitivity Liquid Liquid Liquid 5% (50 mg / ml) 10% (100 mg / ml) 10% 1 / 2.5 / 5 / 10 gm 2 / 5 / 10 / 20 gm 5 / 10 / 20 / 40 gm N / A N / A N / A IgA deficiency; anaphylaxis to polysorbate and IG; hyperprolinemia Cold ethanol fractionation, solvent / detergent treatment; ph4 treatment Cold ethanol fractionation; solvent / detergent treatment; ph4 treatment ph 4; virus and depth filtration; TSE removal 200 µg / ml Average 106 μg / ml 50 mcg / ml Maltose Maltose L-proline 10% (100 mg / ml) Maltose 9% (90 mg / ml) Maltose No sugar 30 mmol / L 30 mmol / L Trace amounts <10 mmol / L days Not tested in PI, cannot be done in ITP N / A 24 months at +2 C to +25 C (36 F to 77 F) from the date of manufacture; do not freeze 24 months at +2 C to +8 C (36 F to 46 F) from the date of manufacture; within the first 12 months of this shelf-life, the product may be stored up to 6 months at +25 C (77 F); after storage at +25 C (77 F) the product must be used or discarded; do not freeze 24 months 24 months 30 months N/A N / A N / A 2 25 C; do not freeze; do not shake ml / kg / min; flush with NS or D5W ml / kg / min; flush with NS or D5W ml / hr / site; max 50 ml / hr for all sites combined While every effort has been made to ensure the accuracy and completeness of the information presented, the author, editor, or publisher cannot be responsible for any errors or omissions. All provided information is obtained from FDA approved product information ASD Healthcare. Chart updated November 2015.
8 Others aspire. ASD Healthcare delivers. When you re in the business of saving lives, you depend on exceptional customer service from your healthcare partners. So when you want a life-saving medication within hours, or need an extensive range of plasma-derived and recombinant therapeutics, connect with ASD Healthcare. Our people are here to help you get the products you need, when you need them. That s standard business for us, a part of our True Blue culture that makes going the extra mile an ordinary part of our day. Others aspire to meet our exceptional service. ASD Healthcare simply delivers. Convenient Connection ASD Healthcare makes it easy to order and reorder your inventory any time, any day, anywhere. Connect at Customer Service Emergency on-call phone orders 365 / 24 / 7 Expedited orders for same-day delivery in 48 states Expertise and resources for access to critical care products Your Patients. Your Purpose. Our Priority.
Hyper-Immune Globulin
Cytomegalovirus Cytogam Intramuscular GamaSTAN S/D Hepatitis B HepaGAM B HyperHEP B S/D Nabi - HB Rabies HyperRAB S/D IMOGAM Rabies - HT Tetanus HyperTET S/D (D) HyperRho S/D RhoGAM UF PLUS Rhophylac WinRho
More informationImmune Globulin Comparison Table
I. Formulation data Gamunex /IGIVnex Gammagard Liquid Privigen Vivaglobin Formulation Lyophilized Liquid Liquid Liquid Liquid Concentration 5% or 10% upon reconstitution Administration set provided? IgA
More informationBDI Pharma, LLC 2018 Product Reference Charts
BDI Pharma, LLC 2018 Product Reference Charts Protein Therapies Intravenous Immune Globulin (10%) 800.948.9834 www.bdipharma.com BIVIGAM NF ADMA Biologics Flebogamma 10% DIF GAMMAGARD LIQUID Gammaked Kedrion
More informationKnow your IVIg options for primary immunodeficiency
Please see full on following page Please see full prescribing information for Privigen, including boxed warning, in pocket. Please see full above See full prescribing information for full boxed warning.
More informationDrug Class Prior Authorization Criteria Immune Globulins
Drug Class Prior Authorization Criteria Immune Globulins Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy has been developed through review of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immunoglobulin for Bacterial Infection in HIV Positive Children Reference Number: CP.CPA.42 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immunoglobulin for Parvovirus B19 Infection Reference Number: CP.CPA.90 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder
More informationSubcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Mai Thị Bích Ngọc
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases Mai Thị Bích Ngọc Background Primary immunodeficiency diseases (PIDD): group of over 150 disorders
More informationDisclosure. IVIg Medication Safety: Facts and Fantasies associated with Use. Goals and Objectives. What is IVIG or IGIV?
IVIg Medication Safety: Facts and Fantasies associated with Use. Jerry Siegel, PharmD, FASHP Clinical Associate Professor, The Ohio State University College of Pharmacy Columbus, Ohio Disclosure I have
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immunoglobulin for Paraneoplastic Disorders Reference Number: CP.CPA.89 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.142 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationClinical Policy: Immune Globulins Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid
Clinical Policy: Reference Number: CP.PHAR.103 Effective Date: 08/12 Last Review Date: 09/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy
More informationPrimary Diagnosis: Diagnosis Code(s) (if known): Individual s Weight (lbs) (kg)
Request Date: Initial Request Buy and Bill Individual s Name: Insurance Identification Number: Subsequent request Date of Birth: Individual s Phone Number: Primary Diagnosis: Diagnosis Code(s) (if known):
More informationAbbreviated Class Review: Immunoglobulin G. Month/Year of Review: March 2014 End date of literature search: January 1, 2014 PDL Class: None
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSubcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency
Subcutaneous Immune Globulin: Alternative Therapeutic Pathway for Patients With Primary Immunodeficiency EDUCATIONAL OBJECTIVES Upon completion of this program, participants should be better able to: 1.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immunoglobulin for Aneurysm in Kawasaki Syndrome Reference Number: CP.CPA.86 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationSCIG: (Immune globulin SQ) Hizentra, Vivaglobin, Gammagard Liquid, Gamunex- C, Gammaked, Hyqvia Page 1 of 6
Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 04/1 Revision Date(s): 02/16 Developed By: Medical Criteria Committee Effective Date: 0/01/1 SCIG: (Immune globulin SQ) Hizentra,
More informationIVIg. Treatment With Privigen. Proven protection Designed for stability. Your guide to USED IN US HOSPITALS SINCE 2010
# 1 IVIg USED IN US HOSPITALS SINCE 2010 Your guide to Treatment With Privigen For people with primary immunodeficiency (PI) Proven protection Designed for stability Please see full Important Safety Information
More informationImmune Globulin. Clinical Overview Program BioScrip Inc. All rights reserved BioScrip Inc. All rights reserved.
Immune Globulin Clinical Overview Program Objectives Discuss Autoimmune disorders Describe IG structure, properties and clinical implications Discuss IG product usage, storage and mixing guidelines Discuss
More informationClinical Policy: Immune Globulins Reference Number: ERX.SPMN.129
Clinical Policy: Immune Globulins Reference Number: ERX.SPMN.129 Effective Date: 03/14 Last Review Date: 09/16 Revision Log Coding_Implications See Important Reminder at the end of this policy for important
More informationIntravenous Immune Globulins (IVIG)
Intravenous Immune Globulins (IVIG) Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, and Privigen Subcutaneous
More informationIMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL
PRIMARY IMMUNODEFICIENCIES IMMUNOGLOBULINS: ONE SIZE DOESN T FIT ALL IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL 1 PRIMARY IMMUNODEFICIENCIES ABBREVIATIONS IG IPOPI IV PID SC Immunoglobulins
More informationIVIG Immune Globulin Bivigam, Carimune NF, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Privigen
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.20.03 Subject: IVIG Page: 1 of 13 Last Review Date: December 2, 2016 IVIG (intravenous immunoglobulin)
More informationImmune Globulins. Subcutaneous Immune Globulin: Cuvitru, Hizentra and HyQvia
Immune Globulins Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, and Privigen Subcutaneous Immune Globulin:
More informationDATA SHEET RHESONATIV. NAME OF THE MEDICINE Rhesonativ 625 IU/mL, solution for injection
DATA SHEET RHESONATIV NAME OF THE MEDICINE Rhesonativ 625 IU/mL, solution for injection DESCRIPTION Rhesonativ contains 625 IU of human anti-d immunoglobulin. Rhesonativ is presented as a solution for
More information1 Ig. Prescribed for PI
1 Ig # Prescribed for PI Hizentra is a prescription medicine used to treat primary immune deficiency (PI) in patients 2 years and older. *Ig=Immunoglobulin Please see full on pages 12 13 and full prescribing
More informationIMMUNE GLOBULIN THERAPY
IMMUNE GLOBULIN THERAPY Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationQuality and Clinical Safety of Immunoglobulin Therapies (Regulator s Perspective)
Jacqueline.Kerr@pei.de Department of Immunology Paul-Ehrlich-Institut Langen, Germany Quality and Clinical Safety of Immunoglobulin Therapies (Regulator s Perspective) DISCLAIMER Any opinions/recommendations
More informationCase Management of the Challenging IgG Patient: Clinical Considerations for the Most Effective and Safe Therapy
Case Management of the Challenging IgG Patient: Clinical Considerations for the Most Effective and Safe Therapy By Jerry Siegel, PharmD, FASHP Adapted by Jeannie Counce and Nancy Kramer, RN, BSN, CRNI
More informationImmune Globulins Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: May 18, 2016 Renewal Date: August 16, 2017 Immune Globulins Drug Class Prior Authorization Protocol This policy has been developed through review of medical literature,
More informationSPECIALTY GUIDELINE MANAGEMENT
POLICY SPECIALTY GUIDELINE MANAGEMENT Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex -C, Octagam, and Privigen I.
More informationPolicy. Medical Policy Manual Approved: Do Not Implement Until 1/31/19. Intravenous Immune Globulin (IVIG) Therapy
Intravenous Immune Globulin (IVIG) Therapy NDC CODE(S) 59730-6502-XX - Bivigam 5 g protein 59730-6503-XX - Bivigam 10 g protein 44206-0416-XX - Carimune NF 3 g protein 44206-0417-XX - Carimune 6 g protein
More informationModular Program Report
Modular Program Report The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Immune Globulin Effective Date 10/15/2017 Next Review Date.10/15/2018 Coverage Policy Number..5026 Table of Contents Coverage Policy... 1 General Background...
More informationClinical Policy: Eltrombopag (Promacta) Reference Number: ERX.SPA.71 Effective Date:
Clinical Policy: (Promacta) Reference Number: ERX.SPA.71 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationIMMUNE GLOBULIN (IVIG AND SCIG) Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical
Brand Name Generic Name Length of Authorization Bivigam IVIG Per Medical Guidelines Carimune IVIG Per Medical Guidelines Flebogamma IVIG Per Medical Guidelines Gammagard IVIG/SCIG Per Medical Guidelines
More informationPOLICY Document for Intravenous Immune Globulin (IVIG)
'-..-Ct.I t.j..l.l ~L..,r. V. Family of health care plans CV$ Caremark POLICY Document for Intravenous Immune Globulin (IVIG) The overall objective of this policy is to support the appropriate and cost
More informationIntravenous Immune Globulins (IVIG)
Intravenous Immune Globulins (IVIG) Intravenous Immune Globulin (IVIG): Bivigam, Carimune NF, Flebogamma DIF, Gammagard Liquid, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, and Privigen Subcutaneous
More informationDrug Infusion Site of Care Policy
Drug Infusion Site of Care Policy Policy Number: 5.02.538 Last Review: 6/1/2018 Origination: 7/1/2017 Next Review: 6/1/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will NOT provide coverage
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Promacta) Reference Number: CP.PHAR.180 Effective Date: 03.01.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationCOMMENTARY. 278 Journal of Managed Care Pharmacy JMCP April 2007 Vol. 13, No. 3
COMMENTARY nn Expert Opinion Regarding Clinical and Other Outcome Considerations in the Formulary Review of Gamma globulin is the treatment of choice for many primary immunodeficiencies (PIDs) and autoimmune
More informationEvolving Uses of IVIG in myositis
Evolving Uses of IVIG in myositis Rossitza I. Chichkova, MD, MS Associate Professor Depts of Neurology and Internal Medicine University of South Florida, Tampa, FL Immune Function In Normal State: Protects
More informationImmunoglobulins for Intravenous Administration (IVIGs) How to Use Them & Do They Differ?
Immunoglobulins for Intravenous Administration (IVIGs) How to Use Them & Do They Differ? Tor-Einar Svae, Medical Engineer Senior Vice President, Scientific & Medical Affairs, Immunology & Hematology Octapharma
More informationLife back in their hands 1 3
Life back in their hands 1 3 11153 Evogam NZ Updated HCP Brochure Update FA5 New Zealand s own SCIg 1 New Zealand plasma. New Zealand self-sufficiency. 1,4,5 EVOGAM is manufactured from plasma donated
More informationPHARMACOPOEIA MONOGRAPH
MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION Human coagulation factor IX PHARMACOPOEIA MONOGRAPH PM.3.3.2.0004.15 First Edition The present Pharmacopoeia Monograph applies to human coagulation factor IX
More informationInfusion of intravenous gamma globulin (immunoglobulins)
Infusion of intravenous gamma globulin (immunoglobulins) OBJECTIVES Intravenous gamma globulin therapy is indicated for replacement therapy in patients with primary and secondary antibody deficiency syndromes.
More informationThe University of Mississippi Medical Center The University of Mississippi Health Care. Pharmacy and Therapeutics Committee Medication Use Evaluation
The University of Mississippi Medical Center The University of Mississippi Health Care Pharmacy and Therapeutics Committee Medication Use Evaluation June 2012 Objective The goal of this medication use
More informationCOMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)
COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH) HUMAN ALBUMIN 20 % BEHRING Rev.: 05-MAR-2008 / PEI approval 26.02.08 Supersedes previous versions Rev.: 28-NOV-2007 / Adaptation to Core SPC Rev.: 02-JAN-2007
More information1 WHAT OCTAGAM 50 mg/ml IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER Octagam 50 mg/ml, solution for infusion Human Normal Immunoglobulin (IVIg) Read all of this leaflet carefully before you start using this medicine. - Keep this
More informationHuman Zoster Immunoglobulin, solution for intramuscular injection.
Product Information Zoster Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Zoster Immunoglobulin, solution for intramuscular injection. DESCRIPTION Zoster Immunoglobulin-VF is a sterile, preservative-free
More informationSandoglobulin. Product Information. Australia NAME OF THE MEDICINE. Human normal immunoglobulin for intravenous injection DESCRIPTION
Product Information Sandoglobulin Australia NAME OF THE MEDICINE Human normal immunoglobulin for intravenous injection DESCRIPTION Sandoglobulin is a sterile, lyophilised preparation for reconstitution,
More informationAugmentation Therapy. The Specific Therapy for Alpha-1 Lung Disease. Skinny Little Reference Guide
Augmentation Therapy The Specific Therapy for Alpha-1 Lung Disease Skinny Little Reference Guide INTRODUCTION The FDA-approved therapy for the treatment of Alpha-1-related lung disease, specifically emphysema,
More informationHuman Hepatitis B Immunoglobulin, solution for intramuscular injection.
New Zealand Data Sheet Hepatitis B Immunoglobulin-VF NAME OF THE MEDICINE Human Hepatitis B Immunoglobulin, solution for intramuscular injection. DESCRIPTION Hepatitis B Immunoglobulin-VF is a sterile,
More informationPatient information. Subcutaneous Immunoglobulin Therapy and Home Treatment ( SCIG) Infection and Immunity Directorate PIF 1443 V2
Patient information Subcutaneous Immunoglobulin Therapy and Home Treatment ( SCIG) Infection and Immunity Directorate PIF 1443 V2 An overview of subcutaneous infusion of Immunoglobulin Many patients with
More informationApplications of this product for conditions other than those addressed in this policy are considered OFF-LABEL and are not addressed in this policy.
Subject: Intravenous infusion Immune Globulin (IVIg) Original Effective Date: 12/6/2007 Policy Number: MCP-043 Revision Date(s): 4/27/2011;1/22/2013 Review Date(s): 4/27/2011;1/22/2013, 12/16/2015; 3/30/2016;
More information3. PHARMACEUTICAL FORM Solution for infusion. A clear, slightly viscous liquid; it is almost colourless, yellow, amber or green.
1. NAME OF THE MEDICINAL PRODUCT Albutein 250 g/l, solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human albumin Albutein 250 g/l is a solution containing 250 g/l of total protein of
More informationInformation for professionals for Cytotect CP Biotest: Biotest (Switzerland) AG Complete information for professionals DDD Print
Information for professionals for Cytotect CP Biotest: Biotest (Switzerland) AG Complete information for professionals DDD Print Composition 1 ml solution contains: Active ingredients:. plasma proteins
More informationPREMIER START SM SAMPLE REQUEST FORM
PREMIER START SM SAMPLE REQUEST FORM SECTION A SECTION B SECTION C PATIENT INFORMATION* Name Contact Phone Patient Address (no PO Boxes) Diagnosis (ICD-10) Medical Benefits Insurance Pharmacy Benefit *Naïve
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT GAMMANORM, 165 mg/ml, solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Human normal immunoglobulin (SC/IMIg) Human
More informationExcellence and Innovation in Manufacturing
Excellence and Innovation in Manufacturing The leading Ig therapies of CSL Behring Please see full Important Safety Information for Hizentra and Privigen on pages 16 17 and full prescribing information
More informationProperties of treatment options for hemophilia A and von Willebrand disease (VWD)
Properties of treatment options for hemophilia A and von Willebrand disease (VWD) ALPHANATE is the only FVIII/VWF complex to offer the convenience of a large 2000-IU vial size with low diluent volume Five
More informationR ECOMBINANT FACTOR VIII COMPARISON CHART
R ECOMBINANT FACTOR VIII COMPARISON CHART Advate by Shire. of 13 1, BAXJECT II monograph: www.baxter.ca/en/downloads/product_information/advate_pm_dec2013_en.pdf 28 C for up to 6 all ages. Currently available
More informationIntravenous Immune Globulin (IVIg)
Policy Number Reimbursement Policy IVIG04272010RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 10/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationPRODUCT MONOGRAPH GAMUNEX. Immune Globulin Intravenous (Human), 10% Manufactured by Chromatography. Injectable Solution. Passive Immunizing Agent
PRODUCT MONOGRAPH GAMUNEX Immune Globulin Intravenous (Human), 10% Manufactured by Chromatography Injectable Solution Passive Immunizing Agent Manufactured by: Grifols Therapeutics Inc. 8368 U.S. 70 Bus.
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Immune Globulin Subcutaneous [Human] Effective Date... 5/15/2012 Next Review Date.5/15/2013 Coverage Policy Number... 8004 Table of Contents Coverage Policy... 1 General
More informationCONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml]
CONSUMER MEDICINE INFORMATION (CMI) OCTAGAM 10% [100 mg/ml] Human Normal Immunoglobulin Solution for Intravenous Infusion. OCTAGAM 10% [100 mg/ml] is available in single use bottles of 20 ml, 50 ml, 100
More informationEVOGAM. Information for patients Evogam NZ Patient Brochure Update FA3
EVOGAM Information for patients 11179 Evogam NZ Patient Brochure Update FA3 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have been
More informationImmune Globulin. Prior Authorization
MB9423 Covered Service: Yes when meets criteria below Prior Authorization Required: Additional Information: Yes as shown below Requires prior authorization through Navitus and is considered medically appropriate
More informationImmune Globulin Therapy
Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO 08/26/2011 Section: Prescription Drugs Place(s) of Service: Outpatient
More informationPreparation and Administration
Preparation and Administration A guide for healthcare professionals XOLAIR IS INDICATED FOR: Adults and adolescents (aged 12 years) with moderate-to-severe persistent asthma who have a positive skin test
More informationModular Program Report
Modular Program Report The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product
More informationGammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin
Package leaflet: Information for the user Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin Read all of this leaflet carefully before you start using this medicine
More informationCSL Behring LLC Albuminar -25 US Package Insert Albumin (Human) USP, 25% Revised: 01/2008 Page 1
Page 1 CSL Behring Albuminar -25 Albumin (Human) USP, 25% R x only DESCRIPTION Albuminar -25, Albumin (Human) 25%, is a sterile aqueous solution of albumin obtained from large pools of adult human venous
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Immune Globulins Reference Number: CP.PHAR.103 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important Reminder
More informationHuman Cytomegalovirus Immunoglobulin, solution for intravenous injection.
Product Information CMV Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Cytomegalovirus Immunoglobulin, solution for intravenous injection. DESCRIPTION CMV Immunoglobulin-VF is a sterile, preservative
More informationQuick Reference: Plasma Protein Products
All plasma protein products a contraindicated in patients with any of the following: Hypersensitivity to the product or any ingdient in the formulation or component of the container. Pvious anaphylactic
More informationCONSUMER MEDICINE INFORMATION LEAFLET
CONSUMER MEDICINE INFORMATION LEAFLET Read all of this leaflet carefully before you start using this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask
More informationABIOpure TM Viral (version 2.0)
ABIOpure TM Viral (version 2.0) DNA/RNA Extraction Handbook Cat No: M561VT50 FOR RESEARCH USE ONLY Table of Contents Contents Page Kit Components 3 Precautions 3 Stability & Storage 4 General Description
More informationAugmentation Therapy. The Specific Therapy for Alpha-1 Lung Disease. Skinny Little Reference Guide
Augmentation Therapy The Specific Therapy for Alpha-1 Lung Disease Skinny Little Reference Guide INTRODUCTION The FDA-approved therapy for the treatment of Alpha-1-related lung disease, specifically emphysema,
More informationIg Therapy: One Size Does Not Fit All
Ig Therapy: One Size Does Not Fit All Carla Duff, CPNP, MSN, IgCN Advanced Registered Nurse Practitioner University of South Florida Division of Allergy, Immunology, and Rheumatology 1 Objectives Understand
More informationDME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,
More informationDME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018
G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,
More informationTable 1: In vitro reduction factor during Albumin (Human) 25% manufacturing
Albumin (Human) 25% U.S. License No. 1646 Rx only DESCRIPTION Albumin (Human) 25% is a sterile, liquid preparation of albumin derived from large pools of human plasma. All units of human plasma used in
More informationThere s. to you THAT S WHY THERE S MORE TO GAMUNEX-C. *Chronic inflammatory demyelinating polyneuropathy.
There s more to you THAT S WHY THERE S MORE TO GAMUNEX-C YOUR GUIDE FOR THE LONG-TERM TREATMENT OF CIDP * *Chronic inflammatory demyelinating polyneuropathy. Please see Important Safety Information on
More informationMEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT
INFUSION SERVICES & EQUIPMENT Effective Date: August 1, 2017 Review Dates: 10/95, 12/99, 12/01, 11/02, 11/03, 11/04, 10/05, 10/06, 10/07, 10/08, 10/09, 4/10, 4/11, 4/12, 4/13, 5/14, 5/15, 2/16, 2/17, 5/17
More informationHizentra Infusion Guide
Hizentra Infusion Guide Step-by-step instructions for self-administering Hizentra Use this guide only as a supplement to the Hizentra full prescribing information and to personal instruction from your
More informationGammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin
PACKAGE LEAFLET: INFORMATION FOR THE USER Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More informationHuman Normal Immunoglobulin, solution for intramuscular injection.
Product Information Normal Immunoglobulin-VF Australia NAME OF THE MEDICINE Human Normal Immunoglobulin, solution for intramuscular injection. DESCRIPTION Normal Immunoglobulin-VF is a sterile, preservative-free
More informationEVOGAM. Information for patients Evogam 2014 NZ Patient Brochure Update v11
EVOGAM Information for patients 11881 Evogam 2014 NZ Patient Brochure Update v11 Information for patients and caregivers about EVOGAM This booklet is designed to help you follow the training you will have
More informationBioCARE is the Exclusive Distributor of OBIZUR 1
BioCARE is the Exclusive Distributor of OBIZUR 1 24 7 Product Deliveries 24/7 Standard next-day, emergency same-day, and STAT delivery options Unique Distribution Network More than 20 community blood centers
More informationWebinar Wednesdays. November 28, 2018 March 13, :00 pm 8:00 pm ET
Participate from the comfort of your HOME in a LIVE virtual educational program for chronic inflammatory demyelinating polyneuropathy (CIDP) patients and their caregivers. The program features a presentation
More informationJ1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364
G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288
More informationImmune Globulin Therapy
Immune Globulin Therapy Policy Number: Original Effective Date: MM.04.015 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2015 Section: Prescription Drugs Place(s) of Service:
More informationSeptember 6, 2013 ELECTRONIC DELIVERY. Re: CMS 1601 P (Hospital Outpatient Prospective Payment System Calendar Year 2014 Proposed Rule)
September 6, 2013 Marilyn Tavenner Administrator Chief Operating Officer Centers for Medicare & Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200 Independence
More informationSodium chloride and sodium acetate corresponding to sodium Polysorbate µg Water for Injections 82.5 micrograms
PRODUCT INFORMATION gammanorm NAME OF DRUG gammanorm, Human Normal Immunoglobulin (SC/IMIg), 165 mg/ml, solution for intramuscular injection or subcutaneous infusion One vial of 10 ml gammanorm contains
More informationPRESCRIPTION REFERRAL FORM IgIQ SM RESOURCE CENTER BENEFITS INVESTIGATION REQUEST
PRESCRIPTION REFERRAL FORM IgIQ SM RESOURCE CENTER BENEFITS INVESTIGATION REQUEST SECTION A Name Contact Phone Patient Address (no PO Boxes) Sex q M q F SECTION B FAX: 1-866-720-4373 TOLL-FREE: 1-877-355-IGIQ
More informationADULT DRUG REFERENCE Drug Indication Adult Dosage Precautions / Comments
ADENOSINE Paroxysmal SVT 1 st Dose 6 mg rapid IV 2 nd & 3 rd Doses 12 mg rapid IV push Follow each dose with rapid bolus of 20 ml NS May cause transient heart block or asystole. Side effects include chest
More informationSUMMARY OF PRODUCT CHARACTRISTICS
1. NAME OF THE MEDICINAL PRODUCT Purified, Inactivated, Lyophilized Rabies Vaccine, Prepared on Vero Cells INDIRAB 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Qualitative Formula per dose of 0.5 ml (Single
More informationIndication Dosage Instruction Measles 0.25 ml/kg Administer within 6 days of exposure.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAMASTAN safely and effectively. See full prescribing information for GAMASTAN. GAMASTAN (immune
More information